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OBJECTIVES The aim of this study was to investigate the activity of the cardiac renin-angiotensin system
(RAS) in unstable angina (UA).
BACKGROUND Angiotensin (Ang) II locally produced by continuously operating cardiac RAS may affect the
pathophysiology of UA.
METHODS In 35 patients with UA, 32 with stable effort angina (SA) and 21 with atypical chest pain
(controls), cardiac RAS was investigated during coronary angiography after five days of
Holter monitoring by combining the measurement of aorta-coronary sinus gradient for Ang
I and Ang II with the kinetics study of 125I-Ang I. Messenger RNAs (mRNA) for all the
components of RAS were also quantified with the reverse transcriptase-polymerase chain
reaction (RT-PCR) and localized by in situ hybridization in myocardial biopsy specimens
from patients who underwent aorta-coronary bypass surgery.
RESULTS Cardiac Ang II generation was higher in patients with UA than it was in patients with SA
or in controls (p , 0.001) due to increased de novo cardiac Ang I formation and its enhanced
fractional conversion rate to Ang II. Messenger RNA levels for angiotensinogen (AGTN),
angiotensin-converting enzyme (ACE) and Ang II type 1 (AT1) subtype receptors were
higher in patients with UA (p , 0.01) than they were in patients with SA or in control hearts.
Messenger RNAs for AGTN and ACE were almost exclusively expressed on endothelial and
interstitial cells. Angiotensin II formation was correlated with ischemia burden (p , 0.001).
However, the amount of Ang II formed and the expression levels of mRNAs for AGTN,
ACE and AT1 were not related to the time that had elapsed since the last anginal attack.
CONCLUSIONS In patients with UA, cardiac RAS is activated, resulting in increased Ang II formation.
Myocardial ischemia is essential for RAS activation, but it is unlikely to be a direct and
immediate cause of RAS activation. (J Am Coll Cardiol 2001;38:49–55) © 2001 by the
American College of Cardiology
Components of the renin-angiotensin system (RAS) have
been identified in the cardiac tissues of human and various
animal species (1), and the existence of a functional cardiac
RAS continuously forming low levels of angiotensin (Ang)
II has been demonstrated in humans (2). Vascular forma-
tion of Ang II has also been demonstrated in experimental
preparation of isolated vascular tissues (3) and in humans
(4,5). Locally formed Ang II may directly or indirectly affect
the pathophysiology of unstable angina (UA) either induc-
ing coronary vasoconstriction or facilitating norepinephrine
release from vascular nerve endings. In patients with coro-
nary artery disease, angiotensin-converting enzyme (ACE)
inhibition improves myocardial blood flow to ischemic
regions (6). Moreover, clinical trials have shown that early-
administered ACE inhibition improves the prognosis in
patients with myocardial infarction and UA (7), indirectly
suggesting a possible role of RAS in acute coronary syn-
dromes. Increased ACE expression has, in fact, been found
in hypercellular plaques and in areas of clustered macro-
phages and T-lymphocytes of patients with UA (8,9).
Additionally, both Ang II and Ang II type 1 (AT1)
receptors have been detected in close proximity to the
presumed plaque rupture site in patients who died acutely
after myocardial infarction (8). These findings prompted us
to investigate whether cardiac RAS participates in the acute
inflammatory response associated with UA (10–13). There-
fore, we studied cardiac RAS in patients with UA and stable
effort angina (SA) by combining the measurement of the
aorta-coronary sinus gradient of endogenous Ang I and Ang
II with the kinetics study of 125I-Ang I. We also quantified
the messenger RNA (mRNA) levels of the cardiac RAS
components with reverse-transcriptase polymerase chain
reaction (RT-PCR) in myocardial biopsy specimens from
patients with UA and SA who underwent aorta-coronary
bypass surgery.
METHODS
Study population. Thirty-five patients with UA in class
IIB (n 5 12) and IIIB (n 5 23) of the Braunwald
classification, and 32 patients with SA were investigated.
The control group was made up of 21 normotensive patients
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who underwent coronary angiography for atypical chest
pain. Angiography and routine diagnostic procedures did
not reveal any abnormalities. The clinical characteristics of
this study population are reported in Table 1. All the
patients were on oral aspirin and nitrates. Twenty-one and
nine patients in the UA group were on heparin and
calcium-antagonists, respectively.
Patients with recent (within three months) myocardial
infarction, conduction disturbances, heart failure or patients
treated with ACE inhibitors or beta-blockers in the two
weeks preceding the study were not admitted. Patients who
had myocardial ischemia associated with pulmonary edema,
hypotension or threatening arrhythmias at admission were
also excluded.
Biopsy specimens (10 mg to 20 mg) were collected from
the left ventricular free wall in the distribution territory of
the culprit artery from the 10 patients with UA and the six
patients with SA who underwent bypass surgery. Cardiac
specimens were also obtained from the left ventricular free
wall from six donors with no histories or signs of heart
disease whose hearts could not be transplanted for surgical
reasons or due to blood group incompatibility (control
hearts).
The ethical committee of our institution approved the
study protocol, and all patients gave their informed consent
to participate in the study.
Study design and experimental procedure. After admis-
sion, patients received conventional noninvasive antianginal
treatment and underwent a five-day period of Holter mon-
itoring and recording of symptoms (anginal attacks). Cor-
onary angiography was then performed with a measurement
of coronary blood flow (CBF) and blood sampling for the
determination of cardiac oxygen extraction and Ang I and
Ang II assay according to the procedures previously de-
scribed (2). Patients who underwent pulmonary edema,
hypotension or myocardial ischemia and were not respon-
sive to aggressive therapy were excluded from the study.
Measurement of cardiac Ang formation. Cardiac forma-
tion of Ang I and Ang II was expressed as the aorta-
coronary sinus concentration gradient indexed by coronary
flow. In a subgroup of subjects (nine UA, six SA and five
controls), cardiac degradation, conversion and formation of
Ang I and Ang II and the other parameters shown in Table
2 were calculated by studying the kinetics of 125I-Ang I
infusion (3.5 3 106 cpm/min, specific radioactivity of
81.4 TBq/mmol and calculated exposure to radioactivity of
0.6 mrad) as previously described (2,5).
Angiotensin I and Ang II plasma concentrations were
measured by radioimmunoassay as previously described (5).
Quantification of renin, AGTN, ACE, AT1 receptor,
Ang II type 2 (AT2) receptor and chymase mRNA levels.
Total mRNA was isolated from homogenized frozen sam-
ples using TRIzol reagent (BRL-Life Technologies, Mi-
lano, Italy), as outlined by the manufacturer, and reverse
transcribed using oligo dT-20. The RT-PCR studies were
performed using specific primers for glyceraldeyde-3-
phosphate dehydrogenase (GAPDH) (14), renin (15), an-
giotensinogen (AGTN) (14), ACE (16), chimase (17) and
AT1 (18) and AT2 (18) receptors, as previously described
(14).
Localization of AGTN and ACE mRNAs in the myo-
cardium. The in situ hybridization procedure was per-
formed using complementary DNA photobiotin-labelled
probes for GAPDH (pHcGAP, ATCC n.57090), AGTN
(HFBDR96, ATCC n.82996) and ACE (donated by Pro-
fessor Soubrier, INSERM, Hopital Saint-Louis, Paris,
France) as previously described (14). Each stained histolog-
ical section was examined at 4003 magnification.
Statistical analysis. Data are expressed as mean 6 SD.
Comparison between groups was performed using Student t
test for paired and unpaired data or one-way analysis of
variance followed by Tukey’s multiple-range comparison
test, as appropriate. The relation between cardiac Ang II
formation measured by 125I-Ang I kinetics study and that
evaluated by Ang II aorta-coronary sinus gradient and the
relation between the amount of Ang II formed and the time
elapsed since the last ischemic episode were tested by linear
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AGTN 5 angiotensinogen
Ang 5 angiotensin
AT1 5 angiotensin II type 1 receptor
AT2 5 angiotensin II type 2 receptor
CBF 5 coronary blood flow
CVR 5 coronary vascular resistance
GAPDH 5 glyceraldeyde-3-phosphate dehydrogenase
mRNA 5 messenger RNA
PRA 5 plasma renin activity
RAS 5 renin-angiotensin system
RT-PCR 5 reverse transcriptase-polymerase chain
reaction
SA 5 stable effort angina
UA 5 unstable angina
Table 1. Characteristics of Controls and Patients With Angina
Characteristics
Controls
(n 5 21)
Stable
Angina
(n 5 32)
Unstable
Angina
(n 5 35)
Men/Women 15/6 23/9 28/7
Age (yrs) 55 6 12 63 6 7 59 6 13
Weight (kg) 77.5 6 7.2 79.9 6 8.4 76.5 6 8.6
Smoking, n (%) 13 (61) 21 (64) 23 (63)
Cholesterolemia (mmol/l) 4.4 6 0.8 5.3 6 0.9 5.5 6 0.6
Diabetes, n (%) 3 (14%) 7 (22%) 7 (21%)*
Hypertension, n (%) 9 (43%) 14 (44%) 15 (42%)
Left ventricular mass (g/m2) 112 6 14 110 6 12 113 6 14
LVEF (%) 70.2 6 5.1 64.3 6 3.5 65.9 6 5.2
Mean aortic pressure (mm Hg) 95.1 6 11.9 97.2 6 12.8 101.4 6 12.8
Mean angiographic score† — 15.8 6 3.6 16.2 6 4.1
Coronary blood flow (ml/min) 85.1 6 8.4 80.4 6 4.1 82.5 6 12.1
CVR (mm Hg/ml/min) 1.26 6 0.34 1.51 6 0.42 1.57 6 0.42
*p , 0.01; †According to the American Heart Association.
CVR 5 coronary vascular resistance; LVEF 5 left ventricular ejection fraction.
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regression analysis. Statistical significance was taken as p
,0.05.
RESULTS
Clinical course. All the patients with UA and 10 of 32
(33%) patients with SA suffered from ischemic episodes
during the five days of the study period. The total number
of ischemic episodes per patient during the five-day Holter
monitoring were significantly higher in the patients with
UA than they were in the patients with SA for anginal
attacks (7.1 6 0.5 vs. no attack), silent ischemic episodes
(24.7 6 3.8 vs. 2.6 6 0.4, p , 0.01) and overall duration of
ischemia (126 min 6 41 min vs. 5.6 min 6 1.9 min, p ,
0.01). No patient had heart failure, myocardial infarction or
died during the study period. Coronary blood flow and
coronary vascular resistance (CVR) were not significantly
different among the three groups (Table 1).
Cardiac Ang formation. Angiotensin I and Ang II con-
centrations and plasma renin activity (PRA) in peripheral
venous blood did not differ among the various groups
investigated (data not shown). Aorta-coronary sinus gradi-
ent values of both angiotensins were higher in patients with
UA than in patients with SA or in controls (Fig. 1A) (p ,
0.01 for both), without any significant difference between
patients with SA and controls. The values of the aorta-
coronary sinus Ang II concentration in patients with UA
were above the 99% confidence limits (p , 0.001) of the
values found in patients with SA and controls (Fig. 1A).
In all patients with UA, 125I-Ang I kinetics revealed a
significant increase in cardiac Ang I and Ang II formation
and in fractional conversion of 125I-Ang I to 125I-Ang II
(p , 0.05 vs. SA and controls) (Table 2). Angiotensin I
formed by PRA during the transcardiac passage of blood
was low and not significantly different among the three
groups (Table 2).
The majority of the de novo formed Ang II derived from
the conversion of cardiac Ang I, and only 25% was formed
by the conversion of the arterially delivered Ang I (Table 2).
The cardiac Ang II formation indexed by CBF was
1,294 pg/min 6 283 pg/min in patients with UA and
5.6 pg/min 6 1.9 pg/min for patients with SA (p , 0.01).
A very good correlation was found between cardiac Ang
II formation at kinetics study and Ang II aorta-coronary
sinus gradient (r 5 0.97, p , 0.001).
In contrast with the increased cardiac Ang II generation,
the formation of both angiotensins and the Ang I to Ang II
fractional conversion rate by forearm vascular tissues in
patients with UA were not significantly different from that
in patients with SA or in controls (Table 2).
Measurement of mRNA levels for the cardiac RAS
components. The RT-PCR revealed that AGTN, ACE,
AT1, AT2 and chymase genes were expressed in all myo-
cardial ventricular biopsy specimens from patients with
angina and from control hearts (Fig. 2). Conversely, the
expression of mRNA for renin was not detectable. Densi-
tometric ratios revealed overexpression of AGTN, ACE
and AT1 genes in UA versus both SA specimens and
control hearts (p , 0.01) (Fig. 2B). In patients with SA, the
expression of mRNA for AGTN, ACE and AT1 did not
differ from that of controls (Fig. 2). In contrast, AT2
mRNA levels did not significantly differ among the three
groups of patients (Fig. 2). Finally, no significant differences
were detectable in the expression levels of chymase mRNA
among patients with UA, patients with SA and controls
(Fig 2).
Negative and positive controls for in situ hybridization
studies showed that the signal was specific for mRNA and
that the mRNA in the biopsies was intact (Fig. 3C and I).
In biopsy specimens from control hearts (Fig. 3A and B)
and in ventricular myocardium from patients with SA (Fig.
3G and H), mRNA for AGTN and ACE was expressed
only in trace amounts, whereas AGTN and ACE genes
were overexpressed in the myocardium specimens from
patients with UA and were almost exclusively expressed on
the microvessel endothelial and interstitial cells (Fig. 3D
and E).
Table 2. Kinetics Parameters During 125I-Ang I Infusion and Arterial-Venous Concentrations of Endogenous Ang I and II
Cardiac Tissues Forearm Vascular Tissues
Controls
(n 5 5)
Stable
Angina
(n 5 6)
Unstable
Angina
(n 5 9)
Controls
(n 5 5)
Stable
Angina
(n 5 6)
Unstable
Angina
(n 5 9)
125I-Ang I extraction (%) 35.2 6 3.8 33.2 6 4.1 38.3 6 5.1 35.7 6 5.8 34.9 6 4.2 35.3 6 5.1
125I-Ang I to 125I-Ang II conversion rate (%) 24.3 6 4.7 25.1 6 4.9 39.6 6 6.8* 12.1 6 4.3 12.5 6 3.8 12.6 6 5.2
Ang I by PRA (pg/ml) 1.6 6 0.4 1.8 6 0.6 1.7 6 0.6 1.2 6 0.4 1.2 6 0.6 1.2 6 0.5
Ang I by cardiac tissues (pg/ml) 1.9 6 1.5 3.2 6 0.9 13.9 6 3.8† 5.5 6 2.1 5.2 6 1.8 5.6 6 1.8
Total amount of Ang I formed (pg/ml) 3.6 6 1.5 4.9 6 1.2 15.6 6 4.3 6.8 6 2.1 6.5 6 2.7 6.9 6 2.5
125I-Ang II extraction (%) 26.8 6 2.8 27.9 6 1.9 27.5 6 2.3 29.4 6 3.7 29.2 6 2.9 29.5 6 2.4
Ang II by arterially delivered Ang I (pg/ml) 1.1 6 0.6 0.9 6 0.2 2.3 6 1.1* 0.6 6 0.5 0.7 6 0.3 0.6 6 0.4
Ang II by cardiac tissues (pg/ml) 0.9 6 0.3 1.5 6 0.6 6.7 6 5.1† 2.3 6 0.9 2.5 6 0.6 2.7 6 1.1
Total amount of Ang II formed (pg/ml) 2.1 6 0.8 2.3 6 0.7 9.2 6 4.8† 2.9 6 1.4 3.1 6 1.6 3.3 6 1.9
Ang I A-V gradient (pg/ml) 21.8 6 1.6 21.8 6 0.9 8.9 6 3.9* 1.6 6 0.8 1.7 6 1.1 1.6 6 0.8
Ang II A-V gradient (pg/ml) 20.1 6 0.4 0.7 6 0.6 6.9 6 4.8† 0.8 6 1.5 0.9 6 1.2 0.9 6 1.3
*p , 0.05 vs. controls and stable angina; †p , 0.001 vs. controls and stable angina.
Ang 5 angiotensin; A-V 5 atrioventricular; PRA 5 plasma renin activity.
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Myocardial ischemia and RAS activation. Cardiac Ang II
formation was positively related to the overall duration of
ischemia (r 5 0.65, p , 0.01) (Fig. 1B), but the amount of
Ang II formed was not related to the time that had elapsed
since the last ischemic episode or anginal attack (Fig. 1C),
nor were the expression levels of mRNAs for ACE, AGTN
and AT1 in myocardial biopsies related to the time that had
elapsed since the last ischemic episode or anginal attack
(F 5 1.7).
DISCUSSION
Cardiac RAS activation and increased Ang II formation.
The aim of this study was to investigate the activity of
cardiac RAS in UA. The results demonstrate that cardiac
RAS is activated, resulting in an increased Ang II forma-
tion. This finding is supported by the increased aorta-
coronary sinus concentration gradients for both the endog-
enous angiotensins, the 125I-Ang I kinetic study and the
overexpression of mRNAs for ACE, AGTN and AT1
receptors in ventricular myocardium. The 125I-Ang I kinet-
ics study reveals that the increased Ang II generation is
almost completely attributable to the increased Ang I
formation by cardiac tissues and to its conversion to Ang II
via a significant increase in ACE activity. In contrast with
the activation of cardiac RAS, functional activity of forearm
vascular RAS in patients with UA was not significantly
different from that in patients with SA or controls, thus
indicating that the activation of cardiac RAS is essentially
due to local factors that are not related to the systemic
inflammatory reaction commonly associated with UA
(10,11,13).
The increase in cardiac Ang I formation occurred despite
the fact that RT-PCR did not reveal any expression of renin
mRNA in myocardial ventricular biopsy specimens from
patients with UA. This finding does not contradict the
increase in cardiac Ang I formation because renin may enter
the heart either through diffusion in the interstitial space
(19) or through binding to renin binding proteins (20).
Renin is bound to endothelial and subendothelial cells (21).
Although AGTN may diffuse from the blood compartment
Figure 1. Black circles indicate the patients and the controls who performed 125I-Ang I kinetics study. (A) Aortic (A) and coronary sinus (CS) plasma
concentrations of Angiotensin (Ang) I and II in anginal patients and in controls. (B) Relationship between cardiac Ang II formation and overall duration
of ischemia in the five days of Holter monitoring preceding the study of cardiac RAS. (C) The amount of Ang II formed was not related to the time elapsed
since the last ischemic episode or anginal attack (F 5 1.8). Ang 5 angiotensin; RAS 5 renin-angiotensin system; SA 5 stable effort angina; UA 5 unstable
angina.
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into interstitial space (20,21), RT-PCR showed that
AGTN mRNA levels were notably increased in UA pa-
tients, indicating a selective activation of cardiac AGTN
gene expression. Several studies (17,22) have suggested that,
in cardiac tissues, Ang II may be generated by Ang
II-forming pathways other than ACE, in particular by
chymase, a serine-proteinase chymostatin-sensitive enzyme
mainly contained in the mast cells (17). In this study, ACE
mRNA levels in myocardial specimens from patients with
UA and myocardial ACE activity were increased in contrast
with the lack of significant changes in mRNA levels for
chymase. Thus, although the contribution of chymase in
cardiac Ang II formation remains to be further investigated,
the increased Ang II formation in UA patients appears
mainly to occur through the ACE-dependent pathway.
Myocardial cells involved in the RAS activation. All
myocardial cells are provided with AGTN and ACE
mRNAs (1) and are, thus, able to form Ang I and Ang II in
the presence of renin or other AGTN-activating enzymes.
However, in this study, in situ hybridization studies showed
that ACE and AGTN mRNAs were overexpressed almost
exclusively on the endothelial cells of coronary microvessels
and on the interstitial cells, whereas myocytes did not
express any increased levels of these genes. Although the
lower sensitivity of in situ hybridization in comparison with
quantitative analysis does not rule out the possibility that
AGTN and ACE genes may be increased also in myocytes,
our present findings seem to suggest that myocytes are not
directly involved in the activation of myocardial RAS in
patients with UA. Thus, RAS activation in patients with
UA seems confined to particular cellular types of the
myocardium, such as the interstitial and coronary microves-
sel endothelial cells frequently involved in inflammatory
reactions.
Increased expression of mRNA for AT1 receptors. Be-
sides the enhanced mRNA for AGTN and ACE, we found
a selective increase in AT1 mRNA levels in UA myocardial
specimens without any significant changes in AT2 mRNA
levels. The small size of biopsy specimens did not allow
binding studies; thus, the function or density of AT1
receptors could not be investigated. A selective increase in
the number and gene expression of AT1 receptors was
found in human heart after acute myocardial infarction (23),
and an enhanced myocardial expression of AT1 was re-
ported in rats after experimental ischemia/reperfusion (24).
The selective AT1 gene overexpression may depends on a
different regulation of the mechanism for the Ang II
subtype receptors since a different molecular mechanism was
found to regulate Ang II subtype receptor expression in the
rat heart in a cell and subtype specific fashion (25). Angio-
tensin II has been reported to be a potent negative regulator
of AT1 receptor gene in neonatal rat myocytes (26).
However, an enhanced density of Ang II receptors and an
upregulation of the AT1 gene in the presence of increased
Ang II formation were found in isolated myocytes in various
experimental conditions, including myocardial infarction
and heart failure (27,28). Therefore, the downregulation of
an AT1 receptor by Ang II might be confined to neonatal
rat myocytes. In agreement with this hypothesis, in adult rat
heart subjected to an acute pressure overload, Ang II levels
were found to be directly related with AT1 promoter
activity (29). Moreover, this finding suggests that Ang II
provides a positive feedback loop for potentiation of its
effects through the upregulation of the AT1 gene. However,
only specific studies will be able to clarify this particular
issue.
The sites of Ang II formation. In the heart, Ang II may
be formed either in the intravascular or the interstitial
compartment, and both angiotensins, when injected intra-
coronary, do not readily pass from one to the other com-
partment (30). There is experimental evidence that Ang II
formed by renin uptaken from the plasma and bound to the
endothelial cells may pass into the interstitial compartment
(31). Angiotensinogen and ACE mRNAs in biopsy speci-
mens were overexpressed in the interstitial cells and in the
vascular cells of coronary microvessels (Fig. 3D–F) near the
sites for binding renin uptaken from plasma (20,21), thus
suggesting that both angiotensins are probably produced in
the boundary between vascular and interstitial compart-
ments.
Figure 2. (A) Reverse-transcriptase polymerase chain reaction (RT-PCR)
products of angiotensinogen (AGTN), angiotensin-converting enzyme
(ACE), AT1, AT2 and chymase from the myocardium of the control
hearts (CH) and from the hearts of patients with stable effort angina (SA)
and unstable angina (UA). (B) Densitometric quantification of RT-PCR
products of AGTN, ACE and AT1 from human myocardium in a
nonfailing heart, SA and UA hearts. In UA hearts, the levels for AGTN,
ACE and AT1 messenger RNA were significantly increased versus control
hearts and SA hearts (for both p , 0.01). Data are reported as mean 6 SD.
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In spite of the increase in Ang II formation, CVR in
patients with UA did not differ from that in patients with
SA or in controls. This paradoxical finding may be ex-
plained by Ang II production in coronary microvessels
downstream from the resistance vessels, even if the forma-
tion of vasodilating agents, such as nitric oxide, which has
been demonstrated to increase during hypoxia (32), cannot
be ruled out. However, this hypothesis remains to be
proved, and it is worth stressing that Ang II depresses
constitutive nitric oxide synthase (33) and nitric oxide
activity through the increased production of anione-
superoxide via membrane-bound NADH-NADPH driven
oxidases (34).
Significance and mechanism(s) of the increased Ang II
formation. The increased Ang II formation does not ap-
pear to be either an epiphenomenon of the ischemic
episodes, because it was also detectable in patients who had
been free from ischemia on the third and fourth days of
Holter monitoring preceding the study, or a consequence of
myocardial necrosis, because patients investigated had myo-
cardial enzymes within the normal range. Although we
cannot totally rule out the possibility that heparin modulates
RAS activity, only a proportion of patients with UA
received heparin, whereas all the patients showed RAS
activation. Therefore, it is highly unlikely that heparin is
responsible for the increased Ang II formation. Unstable
angina is associated with an acute systemic inflammatory
reaction involving acute phase proteins (11), cytokine for-
mation (12) and circulating lymphocytes (10). Cardiac RAS
activation might be, therefore, another expression of this
reaction. However, the demonstration that Ang II forma-
tion by forearm vascular tissues in patients with UA did not
differ from that in patients with SA or in controls goes
against this hypothesis. The selective activation of cardiac
RAS indicates that local factors play a major role in cardiac
RAS activation. Cardiopulmonary bypass induces an in-
flammatory reaction (35), which might contribute to the
increased ACE and AGTN mRNA expression found in
UA biopsy specimens. However, enhanced Ang II forma-
tion was detected in all the patients with UA investigated at
least five days before surgery. Therefore, even if cardiopul-
monary bypass may have magnified the expression of ACE
and AGTN genes, cardiac RAS activation preceded surgery.
The positive relationship between the amount of Ang II
formed and the burden of ischemia suggests an important
role of myocardial ischemia in RAS activation. This role
needs, however, to be further investigated since no relation-
ship was found between the amount of Ang II formed or the
expression levels of mRNA for AGTN and ACE and the
interval free from anginal attack before cardiac RAS study.
Thus, myocardial ischemia appears to act as a trigger
activating intermediate mechanisms and mediators that
Figure 3. In situ hybridization for angiotensinogen (AGTN) (A,D,G), angiotensin-converting enzyme (ACE) (B,E,H), Glyceraldeyde-3-phosphate
dehydrogenase (C,I) and plasmid vector pB322 (F) in controls (A,B,C) and in patients with unstable (D,E,F) and stable (G,H,I) angina. Magnification 3
400. Positive messenger RNA (mRNA) signal for AGTN (D) and ACE mRNA (E) was detectable in the interstitial and endothelial cells of patients with
unstable angina. On the contrary, mRNA for AGTN (G) and for ACE (H) was not expressed in myocardial biopsy specimens from patients with stable
effort angina.
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seem more directly responsible for the RAS activation.
Since UA may be considered as a series of episodes of
ischemia/reperfusion, we may speculate that cardiac RAS
activation occurs through the production of reactive species
of oxygen that are able to activate the redox sensitive AP-1
promoter of AGTN, ACE and AT1 genes (36). This
explanation, however, remains unsubstantiated and requires
direct evidence.
Conclusions. These results extend current knowledge on
the pathophysiology of UA. Strong evidence has been found
that cardiac Ang II formation is enhanced, AT1 receptor
mRNA levels are selectively increased and coronary mi-
crovessels and myocardial interstitial cells are involved in the
bursts of UA overexpressing mRNA for ACE and AGTN.
Because of the capacity of Ang II to operate both in an
autocrine-paracrine and intracrine fashion, locally increased
Ang II formation may have important consequences for
cardiac function, microvessel adaptation responses to the
increased oxygen demand and fibroblast activation.
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